Literature DB >> 14622949

Immunity and immunization in elderly.

Patrice Bourée1.   

Abstract

As the average life expectancy increases, retired people want to travel. Five to 8% of travellers in tropical areas are old persons. Immune system suffers of old age as the other organs. The number and the functions of the T-lymphocytes decrease, but the B-lymphocytes are not altered. So, the response to the vaccinations is slower and lower in the elderly. Influenza is a great cause of death rate in old people. The seroconversion, after vaccine, is 50% from 60 to 70 years old, 31% from 70 to 80 years old, and only 11% after 80 years old. But in public health, the vaccination reduced the morbidity by 25%, admission to hospital by 20%, pneumonia by 50%, and mortality by 70%. Antipoliomyelitis vaccine is useful for travellers, as the vaccines against hepatitis and typhoid fever. Pneumococcal vaccine is effective in 60%. Tetanus is fatal in at last 32% of the people above 80 years, therefore this vaccine is very important.

Entities:  

Mesh:

Year:  2003        PMID: 14622949     DOI: 10.1016/j.patbio.2003.09.004

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  17 in total

Review 1.  Telomeres and immune competency.

Authors:  Nan-ping Weng
Journal:  Curr Opin Immunol       Date:  2012-05-22       Impact factor: 7.486

2.  Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin.

Authors:  Wei-Chuan Chang; Kevan L Hartshorn; Mitchell R White; Patience Moyo; Ian C Michelow; Henry Koziel; Bernard T Kinane; Emmett V Schmidt; Teizo Fujita; Kazue Takahashi
Journal:  Biochem Pharmacol       Date:  2010-10-28       Impact factor: 5.858

3.  Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges.

Authors:  Sevan Dirmesropian; James G Wood; C Raina MacIntyre; Philippe Beutels; Anthony T Newall
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

4.  Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.

Authors:  Teun Guichelaar; Jeroen Hoeboer; Myra N Widjojoatmodjo; Sylvia S N Reemers; Cécile A C M van Els; Rob Otten; Yvonne van Remmerden; Jolande Boes; Willem Luytjes
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

5.  The aging immune system and its relationship with cancer.

Authors:  Anthony D Foster; Amogh Sivarapatna; Ronald E Gress
Journal:  Aging health       Date:  2011-10-01

6.  Seroepidemiology of tetanus in Hangzhou from 2009 to 2018.

Authors:  Yuyang Xu; Yan Liu; Jian Du; Wei Zheng; Shijun Liu; Xuechao Zhang; Xiaoping Zhang; Jun Wang; Xinren Che; Wenwen Gu; Wei Jiang
Journal:  Hum Vaccin Immunother       Date:  2020-05-27       Impact factor: 3.452

Review 7.  Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly.

Authors:  Tobias R Kollmann; Ofer Levy; Ruth R Montgomery; Stanislas Goriely
Journal:  Immunity       Date:  2012-11-16       Impact factor: 31.745

8.  Enhancement of cytotoxic T-lymphocyte response in aged mice by a novel treatment with recombinant AdIL-12 and wild-type adenovirus in rapid succession.

Authors:  Jian Chen; John Wang; Jun Li; Qi Wu; Fei Chu Lim; Pingar Yang; Hui-Chen Hsu; David T Curiel; John D Mountz
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

9.  Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study.

Authors:  Kazue Takahashi; Patience Moyo; Lorencia Chigweshe; Wei-Chuan Chang; Mitchel R White; Kevan L Hartshorn
Journal:  Virus Res       Date:  2013-10-16       Impact factor: 3.303

10.  Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Musha Chen; Yue Yuan; Yiguo Zhou; Zhaomin Deng; Jin Zhao; Fengling Feng; Huachun Zou; Caijun Sun
Journal:  Infect Dis Poverty       Date:  2021-07-05       Impact factor: 4.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.